Rabbit Human Factor V Antibody

Precipitating polyclonal rabbit antiserum to human coagulation factor V. Plasma factor V is a relatively labile glycoprotein (MW 350,000) which is essential for normal clotting and haemostasis. It is synthesized in hepatocytes and reticuloendothelial cells in the liver. Factor V is present in platelet alpha-granules but not on the surface of the intact platelet. It is released following platelet aggregation and its coagulant activity is distinguishable from plasma factor V. Thrombin activates Factor V to FVa by proteolysis resulting in the release of several polypeptides with molecular weight of 70,000 to 150,000. After clotting he protein is no longer detectable in the serum. FVa binds to receptor sites in the platelet membrane which protects Fva from the action of inhibitors (e.g. protein C) . The concentration of factor V in adult plasma is 1-3 mg/ml. Newborn infants have similar levels. Factor V deficiency is associated with severe haemorrhagic disorder. Congenital deficiency with an autosomal bleeding is relatively rare. It exists in two molecular forms: coagulant activity may be reduced together with factor V antigen levels (impaired synthesis), or low coagulant activity is associated with the presence of a variable level of plasma factor V (abnormal molecules) . Both conditions lead to frequent minor bleedings of skin and mucosal tissues. Acquired deficiency with reduced factor V antigen levels can be a reliable parameter of liver damage in severe liver diseases. Circulating antibodies to factor V acting as neutralizing inhibitors of plasma an platelet factor V have been described. Highly purified Factor V is isolated from pooled human plasma and used for immunization. Freund's complete adjuvant is used in the first step of the immunization procedure.

P12259

Human

Unconjugated

Plasma factor V is a relatively labile glycoprotein (MW 350,000) which is essential for normal clotting and haemostasis. It is synthesized in hepatocytes and reticuloendothelial cells in the liver. Factor V is present in platelet alpha-granules but not on the surface of the intact platelet. It is released following platelet aggregation and its coagulant activity is distinguishable from plasma factor V. Thrombin activates Factor V to FVa by proteolysis resulting in the release of several polypeptides with molecular weight of 70,000 to 150,000. After clotting he protein is no longer detectable in the serum. FVa binds to receptor sites in the platelet membrane which protects Fva from the action of inhibitors (e.g. protein C) . The concentration of factor V in adult plasma is 1-3 μg/ml. Newborn infants have similar levels. Factor V deficiency is associated with severe haemorrhagic disorder. Congenital deficiency with an autosomal bleeding is relatively rare. It exists in two molecular forms: coagulant activity may be reduced together with factor V antigen levels (impaired synthesis), or low coagulant activity is associated with the presence of a variable level of plasma factor V (abnormal molecules) . Both conditions lead to frequent minor bleedings of skin and mucosal tissues. Acquired deficiency with reduced factor V antigen levels can be a reliable parameter of liver damage in severe liver diseases. Circulating antibodies to factor V acting as neutralizing inhibitors of plasma an platelet factor V have been described. Highly purified Factor V is isolated from pooled human plasma and used for immunization. Freund’s complete adjuvant is used in the first step of the immunization procedure.

Cardiovascular Disease, Epigenetics

Delipidated, heat inactivated, lyophilized, stable whole serum, dialyzed against glycine buffer. Sodium azide 1 mg/ml Total protein and IgG concentrations in the antiserum are comparable to those of pooled normal rabbit serum. No foreign proteins added.

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

For research use only.